Sexually Transmitted Disease (STD) Testing Market by Disease Type, Product and Geography - Forecast and Analysis 2023-2027

Sexually Transmitted Disease (STD) Testing Market Forecast 2023-2027

The sexually transmitted disease (STD) testing market size is forecast to increase by USD 29.99 billion, at a CAGR of 5.46% between 2022 and 2027. Market growth hinges on various factors, notably the rising incidence of sexually transmitted diseases (STDs). This trend is further propelled by favorable reimbursement policies and heightened governmental initiatives worldwide. The increased focus on STD prevention and treatment underscores the importance of accessible healthcare services and support systems. Furthermore, advancements in medical technology and treatment protocols contribute significantly to addressing this public health concern. The collaborative efforts between healthcare providers, policymakers, and industry stakeholders are pivotal in driving awareness, diagnosis, and treatment of STDs. These collective actions not only spur market expansion but also promote better healthcare outcomes and overall well-being within communities globally, emphasizing the importance of proactive healthcare measures in combating prevalent health challenges

What will the Size of the Market be During the Forecast Period?

To learn more about this report, Download Report Sample

Market Segmentation

This report extensively covers market segmentation by product (laboratory testing device and POC testing device), disease type (chlamydia, gonorrhea, syphilis, trichomoniasis, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

Market Dynamics and Customer Landscape

The market encompasses various diagnostic tools and techniques used for the early detection of HIV, Gonorrhea, Syphilis, Genital herpes, Human immunodeficiency virus (HIV) related diseases such as AIDS, Hepatitis C virus, Human papillomavirus (HPV), malaria, tuberculosis, and other sexually transmitted infections. This market includes laboratory testing in hospitals and clinics, diagnostic centers, centralized laboratories, decentralized Point of Care (POC) testing, home-based tests, and research institutes. Technological advancements have significantly impacted the STD diagnostics market, enabling faster, more accurate, and less invasive testing methods. Raising awareness about early disease detection is crucial for effective treatment and prevention of the spread of these diseases. The market for STD diagnostics is expected to grow significantly due to the increasing prevalence of these diseases and the ongoing research and development in this field. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver 

The increasing prevalence of STDs is the key factor driving the global market growth. The Sexually Transmitted Diseases (STD) diagnostics market encompasses various Infectious Diseases, including HIV, Gonorrhea, Syphilis, Hepatitis C virus, Human papillomavirus (HPV), and others. According to the Global HIV/AIDS Statistics from the World Health Organization, an estimated 0.7% of the global population aged 15-49 years was diagnosed with HIV in 2020. Centralized laboratories and decentralized Point-of-Care (POC) testing are crucial in detecting these diseases early.

Moreover, key players in the market include Quest Diagnostics, Instruments, Reagents and kits manufacturers, and diagnostic centers. Technological advancements have led to the development of home-based tests for safe and discreet STD trials. Hence, the increasing incidence and prevalence of STDs in several countries across the globe are expected to foster the growth of the global market during the forecast period.

Significant Market Trends

The increasing involvement of various organizations to create awareness about STDs will fuel the global market growth. Health Organizations prioritize early detection and screening of infectious diseases like HIV, Gonorrhea, Syphilis, and others. POC trials for HIV, a preferred method, is implemented to overcome patient and provider barriers, with self-trials gaining popularity in developed countries. The market also witnesses progress in molecular diagnostics for STDs. Centralized laboratory trials in hospitals and clinics and decentralized POC testing using sensors, microsystems, and imaging technologies contribute to enhanced outcomes.

However, unfavorable reimbursement policies and reluctance due to fear, stigma, and privacy concerns hinder market growth. Key players include Quest Diagnostics, providing instruments, reagents, and kits for Human immunodeficiency viruses (HIV), Hepatitis C virus, and Human papillomavirus. Government initiatives and home-based tests aim to spread awareness and reduce cases of STDs, encouraging safe sexual intercourses and addressing contaminated and unclean practices. The growing involvement of various organizations to increase awareness about STDs is expected to increase the demand for STD trials drugs and thereby expected to increase the growth opportunity for the global market during the forecast period.

Major Market Challenge

The limited healthcare services in developing regions are a major challenge to the global market growth. The global market for sexually transmitted disease (STD) diagnostics is of significant importance in the context of infectious diseases such as HIV, Gonorrhea, Syphilis, and Hepatitis C virus. According to AIDS and Behavior, over 32 million people were living with HIV in 2017, with 5.4 million in the Asia-Pacific region and over 25 million in Africa. The scarcity of financial and human resources for medical care in developing regions, including Asia and MEA, hinders the promotion of public health and results in high STD-infected populations.

Moreover, the healthcare systems in these countries often lack skilled healthcare professionals and quality health services, including STD trials. Point-of-care (POC) trials is a technological advancement that aims to address this issue by providing early disease detection at decentralized locations such as hospitals and clinics, diagnostic centers, and even home-based tests. These factors lead to an increased prevalence of HIV, resulting in high rates of mortality and morbidity, which, together with the lack of financial resources for infrastructure and health systems, may hinder the growth of the market during the forecast period.

Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Market Customer Landscape

Who are the Major Market Players?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Abbvie - The company offers STD testing services, specifically for the detection of Hepatitis C, to combat chronic liver disease.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

• AccuBioTech Co. Ltd.
• AdvaCare Pharma
• BIOGENIX Inc. Pvt. Ltd.
• CTK Biotech Inc.
• Everlywell Inc.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Goffin Molecular Technologies
• Hangzhou Biotest Biotech Co. Ltd.
• Hologic Inc.
• Inovio Pharmaceuticals Inc.
• Johnson and Johnson
• LT Labs
• Merck and Co. Inc.

Qualitative and quantitative market growth analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Market?

The market share growth by the chlamydia segment will be significant during the forecast period. Chlamydia infections occur in individuals aged 15-24 years. Health Organizations emphasize the importance of early disease detection to mitigate the spread of these diseases. Point-of-care (POC) trials play a significant role in STD diagnostics, particularly for CT and Neisseria gonorrhoeae (NG). Technological advancements have led to decentralized POC trials, enabling diagnostics in hospitals and clinics, diagnostic centers, and even at home.

Get a glance at the market contribution of various segments   Request Market Research Report Sample PDF

The chlamydia segment shows a gradual increase in the market share of USD 27.63 billion in 2017 and continue to grow by 2021. However, unfavorable reimbursement structures and reluctance toward trials due to fear, stigma, privacy concerns, and the contaminated nature of samples pose challenges to market growth. Major players in the STD diagnostics market include Quest Diagnostics, Instruments, Reagents, and kits manufacturers. Human immunodeficiency virus (HIV), AIDS, and Behavior, and Public Health initiatives promote safe sexual intercourses and spreading awareness to combat the spread of these diseases. Despite these efforts, the increasing number of cases of STDs necessitates continuous innovation and improvement in diagnostics kits and trials technologies. The growth of this segment is primarily attributed to the increasing adoption of the market by residential consumers, which is driven by an increase in the global demand for the Market during the forecast period.

Which are the Key Regions for the Market?

For more insights on the market share of various regions  Request Market Research Report Sample PDF

North America is projected to account for 47% of the global market share growth by 2023. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. 

The market in North America, specifically focused on Sexually Transmitted Diseases (STDs), is predominantly influenced by the US market. Key drivers include the rising prevalence of diseases such as Hepatitis B, HIV/AIDS, HPV, malaria, and tuberculosis. Major players like BD COR MX, Johnson and Johnson, Pfizer, AbbVie, and Abbott contribute significantly to the market due to the availability of diagnostics platforms for negative patient screening and treatment of STDs. At-risk populations, including MSM and pregnant women, are particularly vulnerable to diseases like Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Improved access to healthcare coverage through initiatives like the Affordable Care Act is enhancing the reach of STD trials and treatment for conditions like HIV/AIDS and AIDS. Hence, such factors are driving the market in North America during the forecast period.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides a market research and growth analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by disease type, product, and region.

• Disease Type Outlook 
  • Chlamydia
  • Gonorrhea
  • Syphilis
  • Trichomoniasis
  • Others 
• Product Outlook 
  • Laboratory testing device
  • POC testing device
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Argentina
    • Australia
    • Rest of the world

Market Analyst Overview

The market is a significant segment of the global healthcare industry. With the increasing awareness and acceptance of regular health check-ups, the demand for STD testing is on the rise. The market for STD testing is driven by various factors, including the high prevalence of STDs, increasing government initiatives, and growing private sector participation. The market is also witnessing the entry of new players and technological advancements, leading to innovative testing methods and improved accuracy. The market for STD testing includes various diagnostic techniques such as nucleic acid amplification tests (NAATs), diagnostics platform, pregnancy complications, increased risk of HIV, culture-based methods, and rapid diagnostic tests (RDTs). The market is segmented by diseases, including Chlamydia, Gonorrhea, Syphilis, HIV, and others. The market for STD testing is expected to grow at a significant CAGR during the forecast period. The market is also witnessing the emergence of point-of-care (POC) testing, which is gaining popularity due to its convenience and quick turnaround time. The market for STD testing is a crucial component of disease management and prevention efforts, and it plays a vital role in ensuring public health and safety.

Market Scope
Report Coverage	Details
Page number	162
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 5.46%
Market growth 2023-2027	USD 29.98 billion
Market structure	Fragmented
YoY growth (%)	5.05
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 47%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., AccuBioTech Co. Ltd., AdvaCare Pharma, BIOGENIX Inc. Pvt. Ltd., CTK Biotech Inc., Everlywell Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Goffin Molecular Technologies, Hangzhou Biotest Biotech Co. Ltd., Hologic Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, LT Labs, Merck and Co. Inc., OK Biotech Co. Ltd., Priority STD Testing, QIAGEN NV, and RayBiotech Life Inc.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

 Request Market Research Report Sample PDF

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period.
• Detailed information on factors that will drive the growth of the market between 2023 and 2027
• Precise estimation of the size of the market and its contribution to the parent market.
• Accurate predictions about upcoming trends and changes in consumer behavior.
• Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW).
• A thorough market growth and forecasting analysis of the market’s competitive landscape and detailed information about companies.
• Comprehensive market report analysis of factors that will challenge the growth of market companies.

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch